What are Value Stocks?
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:
- Oncternal Therapeutics ONCT - P/E: 1.98
- Morphic Holding MORF - P/E: 7.29
- Akero Therapeutics AKRO - P/E: 8.31
- Sanofi SNY - P/E: 9.67
- Xenetic Biosciences XBIO - P/E: 0.8
Most recently, Oncternal Therapeutics reported earnings per share at -0.34, whereas in Q1 earnings per share sat at -0.31. Oncternal Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Morphic Holding’s earnings per share for Q2 sits at -0.52, whereas in Q1, they were at -0.55. Morphic Holding does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Most recently, Akero Therapeutics reported earnings per share at -0.57, whereas in Q1 earnings per share sat at -0.42. Akero Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Sanofi’s earnings per share for Q2 sits at 1.41, whereas in Q1, they were at 1.8. Sanofi does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Xenetic Biosciences saw an increase in earnings per share from -0.19 in Q1 to -0.15 now. Xenetic Biosciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.